Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New smart bomb for liver cancer: radiation drug targets tumors only

NCT ID NCT06764316

Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 8 times

Summary

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, some receiving the drug alone and others in combination with other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BAY 3547926 (a drug that delivers radiation directly to cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that targets cancer cells while sparing healthy tissue.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. Only 148 people will take part, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Locally advanced or metastatic and/or unresectable HCC (hepatocellular carcinoma) with histological or cytological confirmation, or non-invasive diagnosis as per American Association for the Study of Liver Diseases (AASLD) criteria in participants with a confirmed diagnosis of cirrhosis. * Demonstrated positive centrally confirmed GPC3 expression by immunohistochemistry (IHC) on tumor sample. * Disease not amenable to, or progressive disease after, curative surgery and/or locoregional therapies of established efficacy such as resection, local ablation, chemoembolization. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. * At least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. as assessed by local site Investigator within 28 days prior to the start of the study treatment. * Adequate bone marrow and organ function Exclusion Criteria: * Fibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular/cholangiocarcinoma subtypes. * Participants with a history or clinical evidence of CNS metastases, unless they meet specific criteria * History of encephalopathy ≥ Grade 2 within the past 12 months * Clinically significant ascites

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barcelona

    RECRUITING

    Barcelona, Barcelona, 08908, Spain

  • Brussel

    RECRUITING

    Brussels, 1200, Belgium

  • Dothan

    RECRUITING

    Dothan, Alabama, 36303, United States

  • Duarte

    RECRUITING

    Duarte, California, 91010, United States

  • Edegem

    RECRUITING

    Edegem, Antwerp, 2650, Belgium

  • Glasgow

    RECRUITING

    Glasgow, Scotland, G12 0YN, United Kingdom

  • Kortrijk

    RECRUITING

    Kortrijk, West Flanders, 8500, Belgium

  • Leuven

    RECRUITING

    Leuven, Flemish Brabant, 3000, Belgium

  • London

    RECRUITING

    London, Greater London, NW3 2QG, United Kingdom

  • London

    RECRUITING

    London, Greater London, W12 0HS, United Kingdom

  • Madrid

    RECRUITING

    Madrid, Madrid, 28050, Spain

  • Madrid

    RECRUITING

    Madrid, 28027, Spain

  • Montpellier

    RECRUITING

    Montpellier, Occitanie, 34298, France

  • Montreal

    RECRUITING

    Montreal, Quebec, H2X 0C1, Canada

  • Montreal

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Pamplona

    RECRUITING

    Pamplona, 31008, Spain

  • Sherbrooke

    RECRUITING

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Sutton

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Tampere

    RECRUITING

    Tampere, Pirkanmaa, 33520, Finland

  • Tokyo

    RECRUITING

    Tokyo, 104-0045, Japan

  • Toronto

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

  • Turku

    RECRUITING

    Turku, Southwest Finland, 20540, Finland

  • Villejuif

    RECRUITING

    Villejuif, 94805, France

  • Xuhui District

    RECRUITING

    Xuhui, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.